DPP-4 Inhibition Ameliorates Pancreatic β-Cell Failure and Improves Glucose Tolerance in the Mouse Model of Wolfram Syndrome

DOI: 10.4236/jdm.2015.52009   PDF   HTML   XML   2,452 Downloads   2,897 Views   Citations


Wolfram syndrome, an autosomal recessive disorder associated with diabetes and optic atrophy, is caused by mutations in the WFS1 gene encoding wolframin, an endoplasmic reticulum membrane protein. Recent development of incretin-based drugs demonstrates promising outcomes for treatment of diabetes mellitus. The aim of this study is to evaluate whether dipeptidyl peptidase-4 inhibition is effective for treating endoplasmic reticulum stress-mediated β-dell failure and impaired glucose tolerance in WFS1-deficient mice (Wfs1/). Wfs1/ mice were orally administrated with vildagliptin (50 mg/kg), a dipeptidyl peptidase-4 inhibitor, twice a day for 4 weeks. The pancreases of these mice were subjected to morphological and biochemical analyses and their glucose tolerance was studied. Electron microscopic studies revealed that vildagliptin reduced number of β-cell containing swollen endoplasmic reticulum in Wfs1/ mice. Vildagliptin treatment increased pancreatic insulin content by 30% in Wfs1/ mice. Oral and intraperitoneal glucose tolerance tests showed improved glucose tolerance in vildagliptin-treated Wfs1/ mice with increased glucose responsiveness of insulin secretion as compared with vehicle-treated mutant mice. These effects by dipeptidyl peptidase-4 inhibition were partly prevented by glucagon-like peptide-1 receptor blockade. These findings provide evidence that activation of the incretin system by dipeptidyl peptidase-4 inhibition plays a protective role against β-cell failure in wolframin-deficiency. Our data suggest that diabetes in patients affected with Wolfram syndrome could be treated by incretin-based drugs. Furthermore, since WFS1 dysfunction could be involved in common forms of type 2 diabetes mellitus, our results strengthen the mechanistic rational of using this drug for the disease.

Share and Cite:

Tanji, Y. , Yamaguchi, S. , Ishigaki, Y. , Katagiri, H. , Oka, Y. and Ishihara, H. (2015) DPP-4 Inhibition Ameliorates Pancreatic β-Cell Failure and Improves Glucose Tolerance in the Mouse Model of Wolfram Syndrome. Journal of Diabetes Mellitus, 5, 72-80. doi: 10.4236/jdm.2015.52009.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Wolfram, D.J. and Wagener, H.P. (1938) Diabetes Mellitus and Simple Optic Atrophy among Siblings: Report on Four Cases. Mayo Clinic Proceedings, 13, 715-718.
[2] Inoue, H., Tanizawa, Y., Wasson, J., Behn, P., Kalidas, K., Bernal-Mizrachi, E., et al. (1998) A Gene Encoding a Transmembrane Protein Is Mutated in Patients with Diabetes Mellitus and Optic Atrophy (Wolfram Syndrome). Nature Genetics, 20, 143-148. http://dx.doi.org/10.1038/2441
[3] Strom, T.M., Hortnagel, K., Hofmann, S., Gekeler, F., Scharfe, C., Rabl, W., et al. (1998) Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness (DIDMOAD) Caused by Mutations in a Novel Gene (Wolframin) Coding for a Predicted Transmembrane Protein. Human Molecular Genetics, 7, 2021-2028. http://dx.doi.org/10.1093/hmg/7.13.2021
[4] Sandhu, M.S., Weedon, M.N., Fawcett, K.A., Wasson, J., Debenham, S.L., Daly, A., et al. (2007) Common Variants in WFS1 Confer Risk of Type 2 Diabetes. Nature Genetics, 39, 951-953.
[5] Franks, P.W., Rolandsson, O., Debenham, S.L., Fawcett, K.A., Payne, F., Dina, C., et al. (2008) Replication of the Association between Variants in WFS1 and Risk of Type 2 Diabetes in European Populations. Diabetologia, 51, 458-463. http://dx.doi.org/10.1007/s00125-007-0887-6
[6] Ishihara, H., Takeda, S., Tamura, A., Takahashi, R., Yamaguchi, S., Takei, D., et al. (2004) Disruption of the WFS1 Gene in Mice Causes Progressive Beta-Cell Loss and Impaired Stimulus-Secretion Coupling in Insulin Secretion. Human Molecular Genetics, 13, 1159-1170.
[7] Yamada, T., Ishihara, H., Tamura, A., Takahashi, R., Yamaguchi, S., Takei, D., et al. (2006) WFS1-Deficiency Increases Endoplasmic Reticulum Stress, Impairs Cell Cycle Progression and Triggers the Apoptotic Pathway Specifically in Pancreatic Beta-Cells. Human Molecular Genetics, 15, 1600-1609. http://dx.doi.org/10.1093/hmg/ddl081
[8] Eizirik, D.L., Cardozo, A.K. and Cnop, M. (2008) The Role for Endoplasmic Reticulum Stress in Diabetes Mellitus. Endocrine Reviews, 29, 42-61. http://dx.doi.org/10.1210/er.2007-0015
[9] Laybutt, D.R., Preston, A.M., Akerfeldt, M.C., Kench, J.G., Busch, A.K., Biankin, A.V., et al. (2007) Endoplasmic Rectium Stress Contributes to Beta Cell Apoptosis in Type 2 Diabetes. Diabetologia, 50, 752-763. http://dx.doi.org/10.1007/s00125-006-0590-z
[10] Buton,J., Foisy, S., Rhodes, C.J., Carpenter, L., Biden, T.J. and Prentki, M. (2001) Protein Kinase Czeta Activation Mediates Glucagon-Like Peptide-1-Induced Pancreatic Beta-Cell Proliferation. Diabetes, 50, 2237-2243. http://dx.doi.org/10.2337/diabetes.50.10.2237
[11] Kitamura, T., Nakae, J., Kitamura, Y., Kido, Y., Biggs 3rd, W.H., Wright, C.V., et al. (2001). The Forkhead Transcription Factor Foxo1 Links Insulin Signaling to Pdx1 Regulation of Pancreatic Beta Cell Growth. Journal Clinical Investigation, 110, 1839-1847. http://dx.doi.org/10.1172/JCI200216857
[12] Hui, H., Nourparvar, A., Zhao, X. and Perfetti, R. (2003) Glucagon-Like Peptide-1 Inhibits Apoptosis of Insulin-Secreting Cells via a Cyclic 5’-Adenosine Monophosphate-Dependent Protein Kinase A- and a Phosphatidylinositol 3-Kinase-Dependent Pathway. Endocrinology, 144, 1444-1455.
[13] Kim, S.J., Winter, K., Nian, C., Tsuneoka, M., Koda, Y. and McIntosh, C.H. (2005) GIP Stimulation of Pancreatic Beta-Cell Survival Is Dependent upon Phosphatidylinositol 3-Kinase (PI3-K)/Protein Kinase B (PKB) Signaling, Inactivation of the Forkhead Transcription Factor Foxo1 and Downregulation of Bax Expression. Journal of Biological Chemistry, 280, 22297-22307.
[14] Shimizu, S., Hosooka, T., Matsuda, T., Asahara, S., Koyanagi-Kimura, M., Kanno, A., et al. (2012) DPP-4 Inhibitor Viildagliptin Preserved β-Cell Mass through Amelioration of Endoplasmic Reticulum Stress in C/EBPB Transgenic Mice. Journal of Molecular Endocrinology, 49, 125-135.
[15] Scheuner, D., Vander Mierde, D., Song, B., Flamez, D., Creemers, J.W., Tsukamoto, K., et al. (2005) Control of mRNA Translation Preserves Endoplasmic Reticulum Function in Beta Cells and Maintains Glucose Homeostasis. Nature Medicine, 11, 757-764. http://dx.doi.org/10.1038/nm1259
[16] Preitner, F., Ibberson, M., Franklin, I., Binnert, C., Pende, M., Gjinovci, A., et al. (2004) Gluco-Incretins Control Insulin Secretion at Multiple Levels as Revealed in Mice Lacking GLP-1 and GIP Receptors. Journal Clinical Investigation, 113, 635-645. http://dx.doi.org/10.1172/JCI200420518
[17] Yusta, B., Baggio, L.L., Estall, J.L., Koehler, J.A., Holland, D.P., Li, H., et al. (2006) GLP-1 Receptor Activation Improves Beta Cell Function and Survival Following Induction of Endoplasmic Reticulum Stress. Cell Metabolism, 4, 391-406. http://dx.doi.org/10.1016/j.cmet.2006.10.001
[18] Cunha, D.A., Ladrière, L., Ortis, F., Igoillo-Esteve, M., Gurzov, E.N., Lupi, R., et al. (2006) Glucagon-Like Peptide-1 Agonists Protect Pancreatic Beta-Cells from Lipotoxic Endoplasmic Reticulum Stress through Upregulation of BiP and JunB. Diabetes, 58, 2851-2862.
[19] Mu, J., Petrov, A., Eiermann, G.J., Woods, J., Zhou, Y.P., Li, Z., et al. (2009) Inhibition of DPP-4 with Sitagliptin Improves Glycemic Control and Restores Islet Cell Mass and Function in a Rodent Model of Type 2 Diabetes. European Journal of Pharmacology, 623, 148-154.
[20] Duttaroy, A., Voelker, F., Merriam, K., Zhang, X., Ren, X., Subramanian, K., et al. (2011) The DPP-4 Inhibitor Vildagliptin Increases Pancreatic Beta Cell Mass in Neonatal Rats. European Journal of Pharmacology, 650,703-707. http://dx.doi.org/10.1016/j.ejphar.2010.10.062
[21] Xu, G., Stoffers, D.A., Habener, J.F. and Bonner-Weir, S. (1999) Exendin-4 Stimulates Both Beta-Cell Replication and Neogenesis, Resulting in Increased Beta-Cell Mass and Improved Glucose Tolerance in Diabetic Rats. Diabetes, 48, 2270-2276. http://dx.doi.org/10.2337/diabetes.48.12.2270
[22] Zhang, X., Wang, Z., Huang, Y. and Wang, J. (2011) Effects of Chronic Administration of Alogliptin on the Development of Diabetes and β-Cell Function in High Fat Diet/Streptozotocin Diabetic Mice. Diabetes Obesity and Metabolism, 13, 337-347. http://dx.doi.org/10.1111/j.1463-1326.2010.01354.x
[23] Shinobu Shimizu, S., Hosooka, T., Matsuda, T., Asahara, S., Koyanagi-Kimura, M., Kanno, A., et al. (2012) DPP4 Inhibitor Vildagliptin Preserves β-Cell Mass through Amelioration of Endoplasmic Reticulum Stress in C/EBPB Transgenic Mice. Journal of Molecular Endocrinology, 49, 125-135. http://dx.doi.org/10.1530/JME-12-0039
[24] Salcedo, I., Tweedie, D., Li, Y. and Greig, N.H. (2012) Neuroprotective and Neurotrophic Actions of Glucagon-Like Peptide-1: An Emerging Opportunity to Treat Neurodegenerative and Cerebrovascular Disorders. British Journal of Pharmacology, 166, 1586-1599.
[25] Shang, L., Hua, H., Foo, K., Martinez, H., Watanabe, K., Zimmer, M., et al. (2014) β-Cell Dysfunction Due to Increased ER Stress in a Stem Cell Model of Wolfram Syndrome. Diabetes, 63, 923-933.
[26] Lu, S., Kanekura, K., Hara, T., Mahadevan, J., Spears, L.D., Oslowski, C.M., et al. (2014) A Calcium-Dependent Protease as a Potential Therapeutic Target for Wolfram Syndrome. Proceedings of National Academy of Sciences of the United States of America, 111, E5292-E5301.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.